AI Stock Analysis - Evolus (EOLS)
Analysis generated October 24, 2025.
Evolus, Inc. is a performance beauty company with a customer-centric approach focused on delivering breakthrough medical aesthetic products. The company’s primary product offering includes Jeuveau®, a proprietary 900 kDa purified botulinum toxin type A formulation for the treatment of moderate to severe glabellar lines. As a relative newcomer in the competitive market of aesthetic medicine, Evolus aims to carve out a niche by prioritizing customer experience and innovation.
Stock Alerts - Evolus (EOLS)
 |
Evolus | March 12 Price is down by -6.1% in the last 24h. |
|
Evolus | March 9 Price is down by -6.1% in the last 24h. |
|
Evolus | March 6 Price is down by -6.4% in the last 24h. |
|
Evolus | March 5 Price is up by 7.2% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Evolus
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 25 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 33,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| App Downloads | 33 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 4 | Sign up | Sign up | Sign up |
| Facebook Followers | 9,598 | Sign up | Sign up | Sign up |
| Instagram Followers | 57,541 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,869 | Sign up | Sign up | Sign up |
| X Followers | 732 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 73 | Sign up | Sign up | Sign up |
| Linkedin Employees | 397 | Sign up | Sign up | Sign up |
About Evolus
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
| Price | $5.04 |
| Target Price | Sign up |
| Volume | 1,322,932 |
| Market Cap | $326M |
| Year Range | $4.13 - $9.73 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at ConferenceMarch 15 - Yahoo Entertainment |
|
Jeuveau (Evolus) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 9 - GlobeNewswire |
|
Evolus, Inc. Q4 2025 Earnings Call SummaryMarch 4 - Yahoo Entertainment |
|
 |
What Catalysts Are Rewriting The Evolus (EOLS) Story After The Guidance ResetFebruary 9 - Yahoo |
|
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform RatingFebruary 9 - Yahoo |
 |
Evolus price target lowered by $4 at Mizuho, here's whyFebruary 4 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 69M | 23M | 46M | -16M | -9.5M | -0.240 |
| Q2 '25 | 69M | 24M | 45M | -17M | -7.8M | -0.270 |
| Q1 '25 | 69M | 22M | 47M | -19M | -13M | -0.170 |
| Q4 '24 | 79M | 29M | 50M | -6.8M | 630,000 | 0.014 |
| Q3 '24 | 61M | 18M | 43M | -19M | -13M | -0.160 |
Insider Transactions View All
| Avelar Rui filed to sell 356,821 shares at $7.2. December 29 '25 |
| MOATAZEDI DAVID filed to sell 354,388 shares at $7.2. December 29 '25 |
| Yamagishi-Dressler Tomoko filed to sell 89,949 shares at $7.5. August 26 '25 |
| Stewart Brady filed to buy 88,629 shares at $6.8. August 18 '25 |
| MOATAZEDI DAVID filed to sell 364,927 shares at $9.9. June 16 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$243.19 N/A | 58 |
 |
Eli Lilly and CompanyLLY |
$989.12 N/A | 62 |
 |
PfizerPFE |
$26.61 N/A | 32 |
 |
AstrazenecaAZN |
$192.01 N/A | 47 |
 |
AbbVieABBV |
$221.45 N/A | 61 |
Read more about Evolus (EOLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Evolus
The Market Cap of Evolus is $326M.
Currently, the price of one share of Evolus stock is $5.04.
The EOLS stock price chart above provides a comprehensive visual representation of Evolus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Evolus shares. Our platform offers an up-to-date EOLS stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Evolus (EOLS) does not offer dividends to its shareholders. Investors interested in Evolus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Evolus are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
